

**September 01, 2026****BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
Scrip Code: 524742

**National Stock Exchange of India Ltd.,**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Receipt of Good Manufacturing Practices (GMP) Compliance Certification by Caplin One Labs Limited (COL), a subsidiary company, from INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), Colombia**

This is to inform the Exchanges that the manufacturing unit of COL, a subsidiary of the Company, located at Survey No. 499/-, 88/-, 500/-, 89/1, Plot No. G-44, G-45 & G-46, Block A and Block B, SIDCO Industrial Estate, Kakkalur, Tiruvallur District, Tamil Nadu, India, has received confirmation of compliance with Good Manufacturing Practices (GMP) from the National Institute for the Surveillance of Food and Drugs (INVIMA), the regulatory authority designated by the Ministry of Health and Social Protection of the Republic of Colombia. INVIMA had concluded that COL complies with the GMP requirements for the manufacture of the following oncology drug products:

| Category    | Dosage Form(s)                               |
|-------------|----------------------------------------------|
| Sterile     | Lyophilized powder for injection (in vials)  |
| Non-Sterile | Tablets (Coated and Uncoated), Hard capsules |

The formal certificate from INVIMA is expected to be received in due course.

This is for your kind information and records.

Kindly acknowledge the receipt.

Thanking You,

Sincerely yours,

**For Caplin Point Laboratories Limited**

**Venkatram G**

**General Counsel & Company Secretary**  
**Membership No A23989**